Protective Effect of Hainosankyuto, a Traditional Japanese Medicine, on Streptococcus pyogenes Infection in Murine Model

Background Streptococcus pyogenes (S. pyogenes) causes various serious diseases including necrotizing fasciitis and streptococcal toxic shock syndrome. One serious problem observed recently with S. pyogenes therapy is attenuation of the antibiotic effect, especially penicillin treatment failure and macrolide resistance. Hainosankyuto, a traditional Japanese medicine based on ancient Chinese medicine, has been used for treatment of infectious purulent diseases in Japan. In this study, we investigated the protective and therapeutic efficacy of Hainosankyuto against S. pyogenes-skin infection. Methodology/Principal Findings A broth microdilution method revealed that Hainosankyuto did not show a direct anti-bacterial effect against S. pyogenes. Force-feeding Hainosankyuto to infected mice for 4 consecutive days increased the survival rate and reduced the size of local skin lesions compared with mice fed PBS. Although we did not find the significant recovery of survival rate in Hainosankyuto administration only after S. pyogenes infection, the sizes of ulcer lesion were significant smaller after Hainosankyuto administration compared with mice fed PBS. No difference was observed in the anti-bacterial effect of Hainosankyuto between macrolide-susceptible and -resistant strains. Blood bactericidal assay showed that the survival rate of S. pyogenes using the blood from Hainosankyuto -treated mice was lower than that using the blood from untreated mice. We also found increased levels of IL-12, IFN-γ and a decreased level of TNF-α in the serum of S. pyogenes-infected mice treated with Hainosankyuto. Mouse peritoneal macrophage from Hainosankyuto-treated mice had significant phagocytic activity and increased mRNA levels of IL-12, IFN-γ and decreased mRNA level of TNF-α compared with control macrophage. Conclusions/Significance Hainosankyuto increased survival rate after S. pyogenes infection and up-regulated both blood bactericidal activity and macrophage phagocytic activity through modulation of inflammatory cytokines. Our data also suggest Hainosankyuto may be useful for the treatment of S. pyogenes infection more prophylactically than therapeutically.

[1]  I. Tatsuno,et al.  Characterization of a virulence-associated and cell-wall-located DNase of Streptococcus pyogenes. , 2010, Microbiology.

[2]  I. Tatsuno,et al.  Clindamycin-Induced CovS-Mediated Regulation of the Production of Virulent Exoproteins Streptolysin O, NAD Glycohydrolase, and Streptokinase in Streptococcus pyogenes , 2009, Antimicrobial Agents and Chemotherapy.

[3]  Eun Bang Lee,et al.  Anti-inflammatory activity of prosapogenin methyl ester of platycodin D via nuclear factor-kappaB pathway inhibition. , 2008, Biological & pharmaceutical bulletin.

[4]  T. Miyase,et al.  Protective effects of a kampo medicine, Hochu-ekki-to (TJ-41) on lethal malarial infection with Plasmodium chabaudi AS in A/J mice , 2007, Journal of Natural Medicines.

[5]  S. Richter,et al.  Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Yee‐Shin Lin,et al.  Cordyceps sinensis mycelium protects mice from group A streptococcal infection. , 2005, Journal of medical microbiology.

[7]  M. Kohanawa,et al.  Endogenous Interleukin-6 Plays a Crucial Protective Role in Streptococcal Toxic Shock Syndrome via Suppression of Tumor Necrosis Factor Alpha Production , 2005, Infection and Immunity.

[8]  T. Hasegawa,et al.  Effect of Antibiotics on Group A Streptococcus Exoprotein Production Analyzed by Two-Dimensional Gel Electrophoresis , 2005, Antimicrobial Agents and Chemotherapy.

[9]  L. Baltina.  Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. , 2003, Current medicinal chemistry.

[10]  P. But,et al.  Antipruritic and antiinflammatory effects of aqueous extract from Si-Wu-Tang. , 2002, Biological & pharmaceutical bulletin.

[11]  I. Brook.  Failure of penicillin to eradicate group A beta-hemolytic streptococci tonsillitis: causes and management. , 2001, The Journal of otolaryngology.

[12]  T. Eisenstein,et al.  Morphine enhances interleukin‐12 and the production of other pro‐inflammatory cytokines in mouse peritoneal macrophages , 2000, Journal of leukocyte biology.

[13]  M. Cunningham,et al.  Pathogenesis of group A streptococcal infections. , 2000, Clinical microbiology reviews.

[14]  D. Metzger,et al.  A Pivotal Role for Interferon-γ in Protection against Group A Streptococcal Skin Infection , 2000 .

[15]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[16]  K. Matsui,et al.  Establishment of Mouse Model for Salmonella Infection and Trial of Immunomodulating Therapy using Hochu-ekki-to , 1997 .

[17]  G. Wolbink,et al.  Inhibition of human complement by β‐glycyrrhetinic acid , 1997, Immunology.

[18]  D. Metzger,et al.  Protection of mice from group A streptococcal skin infection by interleukin-12. , 1995, The Journal of infectious diseases.

[19]  Y. Ozaki.  Studies on antiinflammatory effect of Japanese Oriental medicines (kampo medicines) used to treat inflammatory diseases. , 1995, Biological & pharmaceutical bulletin.

[20]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .